Oct 21, 2022

This is not the first round of funding DeepUII has closed. In July 2020, the company raised its first round of €3.5 million with the support of Alta Life Sciences, Kurma Partners, and Sofimac Innovation, through its Pertinence Invest 2 fund. With that capital injection, the company could cover the financial needs to validate the technology and start the development of the first equipment. 0 DeepUll is once again raising capital . The Spanish company specializing in diagnostic solutions has closed a €13 million financing round in order to move forward with its sepsis early detection platform, company sources said. The financing round has been led by new investors Innvierte, which is part of the Ministry of Science and Innovation, and another investor whose name has not been disclosed. The round has also counted with the participation of current partners Kurma Partners, Alta Life Sciences, UI Investissement, and Axis Participaciones Empresariales. The company, based at the Barcelona Science Park (PCB), will use this capital injection to accelerate the market launch of its first-in-class platform for the early diagnosis of sepsis. Read more about DeepUII with our companion app. Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, and innovation in biotechnology. DeepUII has raised more than €15 million in private funding since its inception DeepUll was born in 2020 to create fast, affordable, and accessible diagnostic solutions with a specific focus on culture-free diagnostics to be able to detect sepsis even before the onset of symptoms. The Catalan company was born out of the hands of Jordi Carrera and Rafel Bru, who had previously founded Stat-Dx, which they sold in 2018 to Qiagen for $191 million (€154 million). Stat-DX developed a diagnostic test capable of processing any type of sample without prior preparation and facilitating the result of up to 48 molecular targets simultaneously. DeepUll’s sepsis product is designed to detect more than 250 different pathogens and fifteen resistance genes in one hour from 10 milliliters of blood. The product will generate phenotypic antimicrobial susceptibility results, without the need for positive blood culture. The product will be a fully automated device so that it can be placed in any clinical setting, such as a laboratory, emergency, or intensive care unit (ICU). DeepUll’s sepsis product is designed to detect more than 250 pathogens This is not the first round of funding DeepUII has closed. In July 2020, the company raised its first round of €3.5 million with the support of Alta Life Sciences, Kurma Partners, and Sofimac Innovation, through its Pertinence Invest 2 fund. With that capital injection, the company could cover the financial needs to validate the technology and start the development of the first equipment. Sepsis causes around eleven million deaths annually, surpassing as of 2018 the estimate of 9.6 million deaths caused by cancer. Sepsis occurs when the body’s immune system response to infection becomes dysregulated. This can cause a cascade of changes that damage multiple organs, leading them to fail, sometimes even resulting in death. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  PlantaDoce , a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.